Phase 2Not yet recruiting
Evaluation of the Safety and Efficacy of Rimonabant on Cognitive impairment in patients with post-COVID-19 Syndrome. (RIMOCOVID-1)
Effects of a CB1 Receptor Antagonist/Inverse Agonist (Rimonabant) on the Improvement of Cognitive Impairment in Patients with Post-COVID-19 Syndrome (RIMOCOVID-1)
- Sponsor
- Sinfatin S.L. (Industry)
- Enrolment
- 80 planned
- Conditions
- Post-COVID-19 syndrome
- Interventions
- Rimonabant 2,5 mg tablets
- Ages
- adults, older adults
- Registry
- CTIS2023-507870-42-00
Full record on the EU Clinical Trials Information System
From the registry
Main objective: To evaluate the efficacy of rimonabant in improving cognitive impairment in patients with post-COVID-19 syndrome compared to placebo.
Primary outcomes
- Change from baseline in cognitive performance measured by the total score of the Symbol Digit Modalities Test (SDMT), being analysed at treatment (V02, V03 and V04) and follow-up (V05) visits.
History
Registered